8/8/2008

Sorin Group has received FDA approval to market its Reply family of single- and dual-chamber pacemakers. The devices are designed for use in patients with sinus node disease and atrioventricular block to decrease unnecessary pacing, which can cause heart failure and atrial fibrillation.

Full Story:
FDAnews

Related Summaries